• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis - Product Image

ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis

  • Published: November 2012
  • 47 pages
  • GlobalData

ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

ASP7374 (UMN-0502) is a recombinant READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher Level of Patient Awareness
6.2.2 Increased Efficacy in the Elderly and Young Children (<2 years old)
6.2.3 Improved Vaccine Side-Effect Profiles
6.2.4 More Efficient Vaccine Manufacturing Process
6.2.5 More Cost-Effective Vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded Breadth of Protection Against Viral Strains
6.4.2 Increased Duration of Protection
6.4.3 T-cell Involvement
7 Pipeline Assessment
7.1 Overview
7.2 Promising Vaccines in Clinical Development
7.2.1 ASP7374 (UMN-0502)
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 Forecasting Methodology
8.4.1 Vaccine Coverage
8.4.2 Vaccines Included
8.4.3 Influenza Vaccine Tender System Assumptions
8.4.4 General Pricing Assumptions
8.4.5 Pricing of Pipeline Agents
8.5 Physicians and Specialists Included in this Study
8.6 Primary Research - Prescriber Survey
8.7 About the Authors
8.7.1 Authors
8.7.2 Global Head of Healthcare
8.8 About Us
8.9 Contact Us
8.10 Disclaimer

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Overall Unmet Needs - Current Level of Attainment
Table 7: Clinical Unmet Needs - Gap Analysis, 2012
Table 8: Seasonal Influenza Vaccines - Phase Pipeline, 2012
Table 9: Product Profile - ASP7374
Table 10: ASP7374 SWOT Analysis, 2012
Table 11: Global Sales Forecasts ($m) for ASP7374 (UMN-0502), 2012-2022
Table 12: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos